GlassScriptPhysician profile
Matthew T Mclaughlin
NPI 1548569965
$1,534.59
in general payments reported to CMS, 2019-2025
20 companies · $318 in 2025
The $318 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $768 · 2021: $11.56 · 2022: $54.11 · 2023: $273 · 2024: $111 · 2025: $318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $701.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $272.81 | 2019-2025 | Airsupra, Breztri, Symbicort |
| Glaxosmithkline, LLC. | $242.29 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.28 | 2019-2025 | Ofev |
| Genzyme Corporation | $130.13 | 2019-2025 | |
| Fresenius Kabi USA, LLC | $124.98 | 2023 | Smoflipid |
| Actelion Pharmaceuticals US, INC. | $77.63 | 2019 | |
| Mylan Specialty L.P. | $71.11 | 2019-2024 | Yupelri |
| Philips North America LLC | $64.83 | 2019 | |
| Pfizer INC. | $58.21 | 2022-2023 | |
| Viatris Specialty LLC | $45.67 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $45.51 | 2019-2025 | |
| Allergan, INC. | $39.70 | 2019 | |
| Shire North American Group INC | $36.52 | 2019 | |
| Circassia INC. | $33.32 | 2019 | |
| Genentech USA, INC. | $32.45 | 2019-2023 | Xolair |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $30.18 | 2025 | Ohtuvayre |
| Insmed, INC. | $29.22 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $19.28 | 2019 | |
| Grifols USA, LLC | $19.25 | 2025 | Prolastin-C Liquid |
| Janssen Pharmaceuticals, INC | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mclaughlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.